<DOC>
	<DOCNO>NCT02446717</DOCNO>
	<brief_summary>The purpose study assess efficacy safety ABT-493 ABT-530 without ribavirin ( RBV ) participants chronic hepatitis C virus , ( HCV ) -infection previously fail treatment direct act antiviral ( DAA ) -containing regimen .</brief_summary>
	<brief_title>A Study Evaluate Efficacy , Safety , Pharmacokinetics ABT-493 ABT-530 With Without Ribavirin Adults With HCV Who Failed Prior DAA Containing Therapy</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>1 . Previous treatment DAAcontaining regimen chronic HCV infection result either ontreatment virologic failure posttreatment relapse 2 . Chronic HCV GT 1 , 4 , 5 , 6infection 1 . History severe , lifethreatening significant sensitivity drug 2 . Female pregnant , plan become pregnant study breastfeeding ; male whose partner pregnant planning become pregnant study 3 . Recent ( within 6 month prior study drug administration ) history drug alcohol abuse could preclude adherence protocol 4 . Positive hepatitis B surface antigen ( HBsAg ) antihuman immunodeficiency virus antibody ( HIV Ab ) 5 . Coinfection one HCV genotype</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>HCV GT5</keyword>
	<keyword>Interferon ( IFN ) free</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>HCV Genotype 4</keyword>
	<keyword>HCV Genotype 5</keyword>
	<keyword>HCV</keyword>
	<keyword>HCV Genotype 6</keyword>
	<keyword>Chronic Hepatitis C</keyword>
	<keyword>HCV Genotype 1</keyword>
	<keyword>Chronic HCV</keyword>
	<keyword>Hepatitis C Genotype 1</keyword>
	<keyword>HCV GT4</keyword>
	<keyword>HCV GT1</keyword>
</DOC>